Impact of MDM2 SNP309T>G polymorphism

Increased risk of developing non small cell lung cancer and poor prognosis in indian patients

Jamsheed Javid, Rashid Mir, M. Masroor, Shazia Farooq, Imtiyaz Ahamad, Prasant Yadav, Maryam Zubari, Pc Ray, Ajaz Ahmad Bhat, Pk Julka, Anant Mohan, Maqbool Lone, Ma Banday, Alpana Saxena

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: MDM2 is an important negative regulator of the TP53 pathway, over expressed in many cancers as oncoprotein. Polymorphisms in the promoter region of the MDM2 gene have been shown to alter protein expression and may, thus play an important role in carcinogenesis. Aim and methods: To test our hypothesis that the MDM2 promoter polymorphisms are associated with risk of non small cell lung cancer, we conducted a hospital-based, case-control study of 136 Indian patients diagnosed with NSCLC and 136 cancer-free controls and investigated the association between genetic variation in the promoter region of MDM2 (c.-51309G4T, rs2279744:g.G4T) and the risk of developing NSCLC by tetra-primer ARMS-PCR and ASO-PCR. Results: Compared with the MDM2-2580TT genotype, we found that the MDM2-309G variant genotypes were associated with an increased risk of NSCLC in Indian patients [OR 3.88 (1.82-8.27) RR 1.94 (1.27-2.96) RD 32.6 (15.7-49.6) p 0.0004 for GG and OR 2.60 (1.49-4.57) RR 1.52 (1.20-1.93) RD 23.16 (10.3-36.0) p 0.0009 for GT genotype]. GG genotype was found to be associated with poor survival outcome of NSCLC patients and in addition significant association was observed with stage (p 0.01) and metastasis status (p 0.002) of NSCLC patients. Conclusion: Genetic polymorphism in cell cycle regulatory genes MDM2 contribute to the risk of developing NSCLC in Indian Patients. In addition G allele was associated with an increased risk and poor survival outcome than T allele.

Original languageEnglish
Pages (from-to)341-346
Number of pages6
JournalJournal of Cancer Science and Therapy
Volume4
Issue number10
DOIs
Publication statusPublished - 19 Nov 2012
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Genotype
Genetic Promoter Regions
Alleles
cdc Genes
Polymerase Chain Reaction
Survival
Oncogene Proteins
Genetic Polymorphisms
Regulator Genes
Case-Control Studies
Neoplasms
Carcinogenesis
Neoplasm Metastasis
Genes
Proteins

Keywords

  • Allele specific oligonucleotide
  • Amplification refractory mutation system
  • MDM2
  • Non small cell lung cancer
  • SNP309T>G polymorphism
  • Tetra-primer ARMS-PCR and ASO-PCR

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Impact of MDM2 SNP309T>G polymorphism : Increased risk of developing non small cell lung cancer and poor prognosis in indian patients. / Javid, Jamsheed; Mir, Rashid; Masroor, M.; Farooq, Shazia; Ahamad, Imtiyaz; Yadav, Prasant; Zubari, Maryam; Ray, Pc; Bhat, Ajaz Ahmad; Julka, Pk; Mohan, Anant; Lone, Maqbool; Banday, Ma; Saxena, Alpana.

In: Journal of Cancer Science and Therapy, Vol. 4, No. 10, 19.11.2012, p. 341-346.

Research output: Contribution to journalArticle

Javid, J, Mir, R, Masroor, M, Farooq, S, Ahamad, I, Yadav, P, Zubari, M, Ray, P, Bhat, AA, Julka, P, Mohan, A, Lone, M, Banday, M & Saxena, A 2012, 'Impact of MDM2 SNP309T>G polymorphism: Increased risk of developing non small cell lung cancer and poor prognosis in indian patients', Journal of Cancer Science and Therapy, vol. 4, no. 10, pp. 341-346. https://doi.org/10.4172/1948-5956.1000165
Javid, Jamsheed ; Mir, Rashid ; Masroor, M. ; Farooq, Shazia ; Ahamad, Imtiyaz ; Yadav, Prasant ; Zubari, Maryam ; Ray, Pc ; Bhat, Ajaz Ahmad ; Julka, Pk ; Mohan, Anant ; Lone, Maqbool ; Banday, Ma ; Saxena, Alpana. / Impact of MDM2 SNP309T>G polymorphism : Increased risk of developing non small cell lung cancer and poor prognosis in indian patients. In: Journal of Cancer Science and Therapy. 2012 ; Vol. 4, No. 10. pp. 341-346.
@article{fe35fe739c2c4255bcf88dcfe4b4265e,
title = "Impact of MDM2 SNP309T>G polymorphism: Increased risk of developing non small cell lung cancer and poor prognosis in indian patients",
abstract = "Background: MDM2 is an important negative regulator of the TP53 pathway, over expressed in many cancers as oncoprotein. Polymorphisms in the promoter region of the MDM2 gene have been shown to alter protein expression and may, thus play an important role in carcinogenesis. Aim and methods: To test our hypothesis that the MDM2 promoter polymorphisms are associated with risk of non small cell lung cancer, we conducted a hospital-based, case-control study of 136 Indian patients diagnosed with NSCLC and 136 cancer-free controls and investigated the association between genetic variation in the promoter region of MDM2 (c.-51309G4T, rs2279744:g.G4T) and the risk of developing NSCLC by tetra-primer ARMS-PCR and ASO-PCR. Results: Compared with the MDM2-2580TT genotype, we found that the MDM2-309G variant genotypes were associated with an increased risk of NSCLC in Indian patients [OR 3.88 (1.82-8.27) RR 1.94 (1.27-2.96) RD 32.6 (15.7-49.6) p 0.0004 for GG and OR 2.60 (1.49-4.57) RR 1.52 (1.20-1.93) RD 23.16 (10.3-36.0) p 0.0009 for GT genotype]. GG genotype was found to be associated with poor survival outcome of NSCLC patients and in addition significant association was observed with stage (p 0.01) and metastasis status (p 0.002) of NSCLC patients. Conclusion: Genetic polymorphism in cell cycle regulatory genes MDM2 contribute to the risk of developing NSCLC in Indian Patients. In addition G allele was associated with an increased risk and poor survival outcome than T allele.",
keywords = "Allele specific oligonucleotide, Amplification refractory mutation system, MDM2, Non small cell lung cancer, SNP309T>G polymorphism, Tetra-primer ARMS-PCR and ASO-PCR",
author = "Jamsheed Javid and Rashid Mir and M. Masroor and Shazia Farooq and Imtiyaz Ahamad and Prasant Yadav and Maryam Zubari and Pc Ray and Bhat, {Ajaz Ahmad} and Pk Julka and Anant Mohan and Maqbool Lone and Ma Banday and Alpana Saxena",
year = "2012",
month = "11",
day = "19",
doi = "10.4172/1948-5956.1000165",
language = "English",
volume = "4",
pages = "341--346",
journal = "Journal of Cancer Science and Therapy",
issn = "1948-5956",
publisher = "OMICS Publishing Group",
number = "10",

}

TY - JOUR

T1 - Impact of MDM2 SNP309T>G polymorphism

T2 - Increased risk of developing non small cell lung cancer and poor prognosis in indian patients

AU - Javid, Jamsheed

AU - Mir, Rashid

AU - Masroor, M.

AU - Farooq, Shazia

AU - Ahamad, Imtiyaz

AU - Yadav, Prasant

AU - Zubari, Maryam

AU - Ray, Pc

AU - Bhat, Ajaz Ahmad

AU - Julka, Pk

AU - Mohan, Anant

AU - Lone, Maqbool

AU - Banday, Ma

AU - Saxena, Alpana

PY - 2012/11/19

Y1 - 2012/11/19

N2 - Background: MDM2 is an important negative regulator of the TP53 pathway, over expressed in many cancers as oncoprotein. Polymorphisms in the promoter region of the MDM2 gene have been shown to alter protein expression and may, thus play an important role in carcinogenesis. Aim and methods: To test our hypothesis that the MDM2 promoter polymorphisms are associated with risk of non small cell lung cancer, we conducted a hospital-based, case-control study of 136 Indian patients diagnosed with NSCLC and 136 cancer-free controls and investigated the association between genetic variation in the promoter region of MDM2 (c.-51309G4T, rs2279744:g.G4T) and the risk of developing NSCLC by tetra-primer ARMS-PCR and ASO-PCR. Results: Compared with the MDM2-2580TT genotype, we found that the MDM2-309G variant genotypes were associated with an increased risk of NSCLC in Indian patients [OR 3.88 (1.82-8.27) RR 1.94 (1.27-2.96) RD 32.6 (15.7-49.6) p 0.0004 for GG and OR 2.60 (1.49-4.57) RR 1.52 (1.20-1.93) RD 23.16 (10.3-36.0) p 0.0009 for GT genotype]. GG genotype was found to be associated with poor survival outcome of NSCLC patients and in addition significant association was observed with stage (p 0.01) and metastasis status (p 0.002) of NSCLC patients. Conclusion: Genetic polymorphism in cell cycle regulatory genes MDM2 contribute to the risk of developing NSCLC in Indian Patients. In addition G allele was associated with an increased risk and poor survival outcome than T allele.

AB - Background: MDM2 is an important negative regulator of the TP53 pathway, over expressed in many cancers as oncoprotein. Polymorphisms in the promoter region of the MDM2 gene have been shown to alter protein expression and may, thus play an important role in carcinogenesis. Aim and methods: To test our hypothesis that the MDM2 promoter polymorphisms are associated with risk of non small cell lung cancer, we conducted a hospital-based, case-control study of 136 Indian patients diagnosed with NSCLC and 136 cancer-free controls and investigated the association between genetic variation in the promoter region of MDM2 (c.-51309G4T, rs2279744:g.G4T) and the risk of developing NSCLC by tetra-primer ARMS-PCR and ASO-PCR. Results: Compared with the MDM2-2580TT genotype, we found that the MDM2-309G variant genotypes were associated with an increased risk of NSCLC in Indian patients [OR 3.88 (1.82-8.27) RR 1.94 (1.27-2.96) RD 32.6 (15.7-49.6) p 0.0004 for GG and OR 2.60 (1.49-4.57) RR 1.52 (1.20-1.93) RD 23.16 (10.3-36.0) p 0.0009 for GT genotype]. GG genotype was found to be associated with poor survival outcome of NSCLC patients and in addition significant association was observed with stage (p 0.01) and metastasis status (p 0.002) of NSCLC patients. Conclusion: Genetic polymorphism in cell cycle regulatory genes MDM2 contribute to the risk of developing NSCLC in Indian Patients. In addition G allele was associated with an increased risk and poor survival outcome than T allele.

KW - Allele specific oligonucleotide

KW - Amplification refractory mutation system

KW - MDM2

KW - Non small cell lung cancer

KW - SNP309T>G polymorphism

KW - Tetra-primer ARMS-PCR and ASO-PCR

UR - http://www.scopus.com/inward/record.url?scp=84869060860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869060860&partnerID=8YFLogxK

U2 - 10.4172/1948-5956.1000165

DO - 10.4172/1948-5956.1000165

M3 - Article

VL - 4

SP - 341

EP - 346

JO - Journal of Cancer Science and Therapy

JF - Journal of Cancer Science and Therapy

SN - 1948-5956

IS - 10

ER -